Plexium, Inc. (Plexium) ndi AbbVie alowa mumgwirizano wapadera wokonza ndi kugulitsa buku la Targeted Protein Degradation (TPD) Therapeutics for neurologic. Mgwirizanowu umaphatikiza luso la AbbVie la neuroscience ndi nsanja ya Plexium ya TPD yomwe imathandizira kuti anthu apeze njira zochiritsira zatsopano zomwe zidavuta kale.
"Mgwirizano wathu ndi AbbVie umatilola kulimbikitsa utsogoleri wathu mu Kuwonongeka kwa Mapuloteni Omwe Akuyang'aniridwa ndikukulitsa luso lathu lapamwamba kwambiri ku matenda amisempha," atero Purezidenti wa Plexium & CEO Percival Barretto-Ko. "Neuroscience ndi imodzi mwamalo ovuta kwambiri ochizira kuti apange mankhwala atsopano, chifukwa cha zovuta za matenda a matenda komanso njira zochepa zomwe zakhala zikuyenda bwino. Ndi nsanja yathu yonse komanso ukatswiri wa AbbVie m'derali, tili ndi mwayi wopeza zosokoneza polimbana ndi zolinga zamtengo wapatali zingapo kuti pamapeto pake moyo wa odwala ukhale wabwino. "
"Kugwirizana ndi Plexium kuzindikira ndi kupititsa patsogolo zosokoneza zatsopano zimagwirizana ndi zoyesayesa za AbbVie zogwiritsa ntchito matekinoloje atsopano kuti apeze chithandizo chamankhwala kwa odwala omwe akudwala matenda a ubongo," anatero Eric Karran, Ph.D., Wachiwiri kwa Purezidenti, Neuroscience Discovery ku AbbVie. "AbbVie imayang'anabe kwambiri pakusintha kwa odwala komanso matekinoloje atsopano omwe angathandizire kupititsa patsogolo chithandizo chamankhwala."
Pansi pa mgwirizanowu, Plexium idzachita kafukufuku wamtsogolo pazolinga za mgwirizano, pambuyo pake AbbVie ali ndi mwayi wosankha mapulogalamu owonjezera kafukufuku ndi chitukuko. Plexium idalandira ndalama zolipiriratu ndipo ndiyoyenera kulandira malipiro owonjezera kuchokera kwa AbbVie, komanso malipiro ochepera pazogulitsa zamalonda, ndipo ili ndi mwayi wochita nawo ntchito yopanga zinthu kuti ibweze ndalama zambiri zachifumu. AbbVie adzakhala ndi udindo pa chitukuko ndi malonda padziko lonse lapansi chifukwa cha mgwirizano.
ZOMWE MUNGACHITE PA NKHANIYI:
- Plexium received an upfront cash payment and is eligible to receive additional payments from AbbVie, as well as tiered royalties on commercialized products, and has the option to participate in product development in return for higher royalty rates.
- Under the terms of the collaboration, Plexium will conduct preclinical research activities for the collaboration targets, after which AbbVie has the option to select programs for additional research and development activities.
- “Neuroscience is one of the most challenging therapeutic areas to develop new drugs, due to the complexity of the disease pathologies and limited number of modalities that have been successful.
